NCT02909777 2026-02-11Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaDana-Farber Cancer InstitutePhase 1 Completed26 enrolled
NCT01742988 2021-05-06Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaCuris, Inc.Phase 1 Completed106 enrolled